The PBS: how Australia decides what a medicine costs

Panels reach for the PBS because it is a small system with every big question inside it: universal access, a fixed public purse, an independent committee making explicit trade-offs, and a lobbying industry on the other side of the table. A candidate who can walk a medicine from the manufacturer to the pharmacy counter has demonstrated more understanding of Australian healthcare in ninety seconds than most manage in an hour.

Here is the version worth holding. The scheme does not decide what a medicine costs; it decides what the patient pays and whether the public pays the rest. Everything interesting — the delays, the headlines about drugs available overseas but not here, the arguments about price — sits in the second decision.

When a doctor prescribes a PBS-listed medicine, the pharmacy dispenses it, the patient pays the co-payment, and the pharmacy claims the balance from the Commonwealth. For a general patient the co-payment is capped at the current general amount; for a concession card holder it is a small fraction of that. If the medicine costs less than the co-payment the patient just pays the price. Above it, the subsidy is unlimited: a cystic fibrosis therapy costing the public hundreds of thousands of dollars a year reaches the patient for the same co-payment as an antibiotic.

The safety net sits on top. Once a family’s co-payments in a calendar year pass a threshold, general patients drop to the concession rate and concession patients to nothing. It is the mechanism that protects people with several chronic conditions from being ruined by the arithmetic of one script at a time. Since 2023, many stable long-term medicines can also be dispensed in sixty-day quantities, halving the number of co-payments a patient pays — a change pharmacies opposed and patients mostly welcomed.

The PBAC meets several times a year and considers submissions from manufacturers. Its central question is not "does this drug work" — the TGA has already answered that — but "is the extra benefit worth the extra cost compared with what we already fund". The measure is incremental cost per quality-adjusted life year, the same currency used by assessment bodies in other countries, and there is no fixed threshold; the committee weighs severity, unmet need and the strength of the evidence alongside the number.

A recommendation is not a listing. The Commonwealth then negotiates price and terms with the manufacturer, and a drug can sit recommended-but-unlisted while that happens. Where the committee rejects a submission, the company may resubmit with a lower price or better evidence, and many eventual listings arrive on the second or third attempt. That is where the headlines come from: a medicine available in the United States or Europe, registered here, and not yet funded. The committee is doing exactly what it exists to do, and the patient in the gap is paying the full price or going without.

Hold both of these at once. The case for the scheme as designed. A fixed public budget has to be rationed somehow, and an independent committee applying a published method is the most defensible way to do it — more defensible than ministers listing whatever drew the most media attention. The scheme delivers some of the lowest patient prices in the world and negotiates hard because it buys for the whole country. The case against how it works. The process is slow, and the delay lands on patients with rare and severe conditions whose evidence base is thin by definition. Confidential pricing makes the trade-offs opaque. And the co-payment is regressive: a flat charge takes more from a low-income general patient who is not quite eligible for a concession card.

Notice that both sides accept the premise that someone has to say no. The disagreement is about how quickly, how transparently, and who bears the cost of the wait — which is the level a panel wants you arguing at.

This arrives in three shapes. The direct one: "How are medicines funded in Australia?" The scenario one: a patient cannot afford a medicine that is registered but not listed. And the disguised one — "Should the government fund every effective treatment?"

For the direct question, walk the script from prescription to claim. For the scenario, know what options exist — compassionate access, resubmission, private purchase — and be honest that none is good. For the disguised question, use the PBAC as your worked example of explicit rationing and say where you would draw the line.

Start with the PBS website itself: the "About the PBS" pages explain the co-payment, the safety net and the listing process in plain language, and the PBAC outcomes pages show real decisions with the reasons given. Then read one Grattan Institute report on medicine pricing, because it is where the sharpest criticism of the scheme lives.

Two pieces here give you the surrounding system. How Australian healthcare is actually structured puts the PBS beside Medicare and the states, and the bulk billing story is the other funding mechanism you will be asked to explain. For the interview formats themselves, see our Australian interview guides.